- Home
- INM vs DRCT Comparison
INM vs DRCT Comparison
Compare INM & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INM | DRCT |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 2.3M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INM | DRCT |
|---|---|---|
| Price | $1.49 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 177.0K | 30.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,942,633.00 | ★ $34,694,000.00 |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.50 | N/A |
| 52 Week Low | $0.58 | $0.04 |
| 52 Week High | $3.34 | $7.21 |
Technical Indicators
Market Signals| Indicator | INM | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 46.11 |
| Support Level | $1.45 | $2.73 |
| Resistance Level | $1.52 | $2.98 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 19.05 | 21.04 |
Price Performance
Historical ComparisonAbout INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.